First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice.

IF 2.5 3区医学 Q3 ONCOLOGY

Oncology Pub Date : 2024-11-11 DOI:10.1159/000542517

Yasutoshi Fujii, Tomokazu Kawaoka, Yuki Shirane, Ryoichi Miura, Hikaru Nakahara, Kenji Yamaoka, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Daiki Miki, Nelson Clair Hayes, Masataka Tsuge, Yuko Nakamura, Kazuo Awai, Shiro Oka

{"title":"First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice.","authors":"Yasutoshi Fujii, Tomokazu Kawaoka, Yuki Shirane, Ryoichi Miura, Hikaru Nakahara, Kenji Yamaoka, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Daiki Miki, Nelson Clair Hayes, Masataka Tsuge, Yuko Nakamura, Kazuo Awai, Shiro Oka","doi":"10.1159/000542517","DOIUrl":null,"url":null,"abstract":"Introduction: Durvalumab plus tremelimumab combination therapy (STRIDE regimen) is a new first-line option for unresectable hepatocellular carcinoma (uHCC), but little real-world data are available to determine which patients are most likely to respond.Methods: This study retrospectively evaluated patients with uHCC who were treated with the STRIDE regimen as the 1st line at our hospital. The primary endpoint of the study was the objective response rate (ORR). We focused on identifying factors associated with cases that had a favorable response.Results: Twenty-one patients were included. In best response, there were 11 partial response cases, with an ORR of 52.4%. Median progression-free survival was 6.8 months, and overall survival did not reach the median time. A high tumor-to-liver ratio of the maximum value of the standardized uptake value (TLR) on baseline fluorodeoxyglucose positron emission tomography (FDG-PET) was associated with response, while TLRs were significantly higher in poorly differentiated uHCC.Conclusion: The STRIDE regimen may be beneficial for systemic therapy-naive uHCC patients. High TLR on baseline FDG-PET could be a potentially useful biomarker for response.","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-6"},"PeriodicalIF":2.5000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000542517","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Durvalumab plus tremelimumab combination therapy (STRIDE regimen) is a new first-line option for unresectable hepatocellular carcinoma (uHCC), but little real-world data are available to determine which patients are most likely to respond.

Methods: This study retrospectively evaluated patients with uHCC who were treated with the STRIDE regimen as the 1st line at our hospital. The primary endpoint of the study was the objective response rate (ORR). We focused on identifying factors associated with cases that had a favorable response.

Results: Twenty-one patients were included. In best response, there were 11 partial response cases, with an ORR of 52.4%. Median progression-free survival was 6.8 months, and overall survival did not reach the median time. A high tumor-to-liver ratio of the maximum value of the standardized uptake value (TLR) on baseline fluorodeoxyglucose positron emission tomography (FDG-PET) was associated with response, while TLRs were significantly higher in poorly differentiated uHCC.

Conclusion: The STRIDE regimen may be beneficial for systemic therapy-naive uHCC patients. High TLR on baseline FDG-PET could be a potentially useful biomarker for response.

查看原文本刊更多论文

在真实世界的临床实践中，Durvalumab 加 Tremelimumab 一线治疗不可切除的肝细胞癌。

导言：Durvalumab加tremelimumab联合疗法（STRIDE方案）是治疗不可切除性肝细胞癌（uHCC）的一线新选择，但几乎没有实际数据可用于确定哪些患者最有可能产生反应：本研究回顾性评估了在本医院接受 STRIDE 方案一线治疗的 uHCC 患者。研究的主要终点是客观反应率（ORR）。我们的重点是找出与获得良好反应的病例相关的因素。在最佳反应中，有11例部分反应，ORR为52.4%。无进展生存期中位数为 6.8 个月，总生存期未达到中位数。基线FDG-PET的肿瘤与肝脏SUVmax（TLR）比值高与应答相关，而分化较差的uHCC的TLR明显更高：结论：STRIDE治疗方案可能对全身治疗无效的uHCC患者有益。结论：STRIDE方案可能对全身治疗无效的uHCC患者有益，基线FDG-PET上的高TLR可能是反应的潜在有用生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.